Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 19/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 18/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 15/20 | 0.45 |
| ▸ | CDK4 | P11802 | 6/20 | 0.45 |
| ▸ | CCND3 | P30281 | 6/20 | 0.45 |
| ▸ | CDK6 | Q00534 | 6/20 | 0.45 |
| ▸ | AURKA | O14965 | 11/20 | 0.44 |
| ▸ | PLK1 | P53350 | 8/20 | 0.43 |
| ▸ | TTK | P33981 | 3/20 | 0.41 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.41 |
| ▸ | PLK2 | Q9NYY3 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795982 | 0.86 | CDK2 (0.45) | CDK2CCNA2CCNA1CDK4CCND3 | |
| SCHEMBL32691354 | 0.84 | MAPT (0.49) | CDK2CCNA2CCNA1CDK4CCND3 | |
| SCHEMBL4956391 | 0.82 | CCNA2 (0.47) | CDK2CCNA2CCNA1 | |
| SCHEMBL6794173 | 0.81 | ROCK2 (0.38) | CDK2CCNA2CCNA1CDK4CCND3 | |
| SCHEMBL2187212 | 0.77 | GRM5 (0.59) | CDK2CCNA2CCNA1 | |
| SCHEMBL2550017 | 0.76 | CDK2 (0.53) | CDK2CCNA2CCNA1CDK4CCND3 | |
| SCHEMBL6792371 | 0.74 | ROCK2 (0.35) | CDK2CCNA2CCNA1CDK4CCND3 | |
| SCHEMBL12240664 | 0.71 | CCNA2 (0.59) | CDK2CCNA2CCNA1CDK4CCND3 | |
| SCHEMBL6790309 | 0.71 | CCNA2 (0.43) | CDK2CCNA2CCNA1CDK4CCND3 | |
| SCHEMBL3588427 | 0.71 | KDM4E (0.40) | CDK2CCNA2CCNA1PLK1TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | CDK2 29/4885CCNA2 270/4885CCNA1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.